-
52 good news stories you may have missed in 2024
22 Dec 2024 02:07 GMT
… with a genetic condition called Leber congenital amaurosis-4, which meant she could …
-
Top 10 Small-Cap Stocks to Watch in 2025
20 Dec 2024 21:13 GMT
… largely targeting orphan conditions like Leber congenital amaurosis 5 (LCA5), bestrophin-1-related …
-
FDA grants rare pediatric disease designation for Leber congenital amaurosis gene therapy
21 Aug 2024 14:09 GMT
… patients with a form of Leber congenital amaurosis, according to a press release … patients with a form of Leber congenital amaurosis, according to a press release …
-
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
19 Dec 2024 13:00 GMT
… cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The …
-
Novel Gene Therapy Improves Vision in Children with Leber Congenital Amaurosis
07 May 2024 13:06 GMT
… 17. These participants suffer from Leber Congenital Amaurosis (LCA), a blindness caused by … Mark Pennesi, MD, PhD.
About Leber Congenital Amaurosis
Leber Congenital Amaurosis (LCA) is a severe genetic …
-
Opus Genetics completes dosing in first cohort of Leber congenital amaurosis trial
28 Mar 2024 18:13 GMT
… therapy, under investigation for Leber congenital amaurosis, demonstrated signs of biological … for the treatment of Leber congenital amaurosis, according to a press … administration in patients with Leber congenital amaurosis resulting from biallelic mutations …
-
Atsena Therapeutics Announces Dosing Completed in Part A of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisis
16 Dec 2024 12:30 GMT
… -101, Atsena’s program for Leber congenital amaurosis type 1 (LCA1), one of …
-
Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
16 Jan 2024 12:30 GMT
… clinical trial in patients with Leber congenital amaurosis caused by biallelic mutations in … ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations … ATSN-101 for GUCY2D-associated Leber congenital amaurosis (LCA1). ATSN-201, which …
-
Aaron Nagiel, MD, PhD, gives interview on the impact of retinal gene therapy procedure conducted at Children's Hospital Los Angeles
14 Dec 2024 13:09 GMT
… , Luxturna, for the treatment of Leber congenital amaurosis (LCA). CHLA was the first …
-
Positive early safety, efficacy data reported for Leber congenital amaurosis gene therapy
06 Dec 2023 15:18 GMT
… gene therapy in GUCY2D-associated Leber congenital amaurosis.
Fifteen patients received unilateral subretinal … gene therapy in GUCY2D-associated Leber congenital amaurosis.
Image: Adobe Stock
There were …